Top

Published in:

01-09-2012 | Review

Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis

Authors: Fausto Petrelli, Karen Borgonovo, Mary Cabiddu, Veronica Lonati, Sandro Barni

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Abstract

The contribution of adjuvant taxanes (T) in cardiovascular toxicity, leukemic risk, and non-cancer-related deaths is unknown when they are added to anthracycline (A)-based chemotherapy for breast cancer. We performed a meta-analysis of published randomized controlled trials (RCTs) to determine the risk of cardiovascular toxicity, leukemia, neurotoxicity, and non-breast cancer-related mortality associated with T added to adjuvant A in breast cancer. PubMed was searched to identify relevant studies. Eligible studies included prospective RCTs in which approved T in combination with A (A + T) were compared with A alone as adjuvant chemotherapy for breast cancer. Summary incidence rates, relative risks (RRs), and 95 % confidence intervals were calculated by means of fixed- or random-effects models. A total of 27,039 patients from 15 RCTs were included. Compared with A alone, A + T was associated with a statistically similar risk of toxicity. Compared with control arms, A + T schedules with less cumulative dose of anthracyclines than control arms were associated with lower severe cardiotoxicity (RR = 0.41, [95% CI 0.26–0.66], P = 0.0002), venous thromboembolic events (RR 0.45, [95% CI 0.26–0.79], P = 0.006), and leukemic risk (RR 0.39; [95%CI 0.18–0.87] P = 0.02), but with an increased risk of non-breast cancer-related mortality (RR = 1.79, [95% CI 1.06–3.04] P = 0.03). In particular, this risk of death is greater when >3 cycles of A precede T in sequential schedules (RR 2.24, [1.2–4.21] P = 0.01). This meta-analysis suggests that A + T-based adjuvant chemotherapy is as toxic as A alone with no significant difference in non-breast cancer-related mortality. However, sequential A + T schedules are associated with less toxicity, but a significant increase in non-breast cancer-related mortality compared with control arms with a greater dose of A.

Available only for authorised users

Early Breast Cancer Trialists’ Collaborative Group Ebctcg (2011) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444. [Epub ahead of print]

Trudeau M, Charbonneau F, Gelmon K et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886–898PubMedCrossRef

Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387PubMedCrossRef

Ellis P, Barrett-Lee P, Johnson L et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373:1681–1692PubMedCrossRef

Martín M, Rodríguez-Lescure A, Ruiz A et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100(11):805–814PubMedCrossRef

Gianni L, Baselga J, Eiermann W et al (2009) Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer. J Clin Oncol 27(15):2474–2481PubMedCrossRef

Boccardo F, Amadori D, Guglielmini P et al (2010) Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Oncology 78(3–4):274–281PubMedCrossRef

Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313PubMedCrossRef

Francis P, Crown J, Di Leo A et al (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: breast international group 02-98 randomized trial. J Natl Cancer Inst 100(2):121–133. (Erratum in: J Natl Cancer Inst 2008;100(22):1655)

10.

Polyzos A, Malamos N, Boukovinas I et al (2010) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic oncology research group (HORG). Breast Cancer Res Treat 119(1):95–104PubMedCrossRef

11.

Martín M, Seguí MA, Antón A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23):2200–2210PubMedCrossRef

12.

Fountzilas G, Skarlos D, Dafni U et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic cooperative oncology group. Ann Oncol 16(11):1762–1771PubMedCrossRef

13.

Buzdar AU, Singletary SE, Valero V et al (2002) Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8(5):1073–1079PubMed

14.

Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983PubMedCrossRef

15.

Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686–3696PubMedCrossRef

16.

Burnell M, Levine MN, Chapman JA et al (2010) Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28(1):77–82PubMedCrossRef

17.

Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24(36):5664–5671PubMedCrossRef

18.

Goldstein LJ, O’Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197. J Clin Oncol 26(25):4092–4099PubMedCrossRef

19.

Martin M, Mackey J, Pienkowski Tet al. (2010) Ten-year follow-up analysis of the BICRG 001 trial confirms superior DFS and OS benefit of adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) over FAC (fluorouracil, doxorubicin, cyclophosphamide) in women with operable node-positive breast cancer. In: Program and abstracts of the 33rd annual San Antonio breast cancer symposium, San Antonio, 8–12 December 2010

20.

Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905PubMedCrossRef

21.

Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302–314PubMedCrossRef

22.

Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

23.

Praga C, Beretta G, Vigo PL et al (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63:827–834PubMed

24.

Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR (1977) Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17–23PubMedCrossRef

25.

Minow RA, Benjamin RS, Lee ET, Gottlieb JA (1977) Adriamycin cardiomyopathy: risk factors. Cancer 39:1397–1402PubMedCrossRef

26.

Pihkala J, Saarinen UM, Lundstrom U et al (1996) Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A:97–103PubMedCrossRef

27.

Kim YD, Lees DE, Lake CR et al (1979) Hyperthermia potentiates doxorubicin-related cardiotoxic effects. J Am Med Assoc 241:1816–1817CrossRef

28.

Lipshultz SE, Lipsitz SR, Mone SM et al (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743PubMedCrossRef

29.

Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G (1993) Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477–479PubMedCrossRef

30.

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792PubMedCrossRef

31.

Gianni L, Munzone E, Capri G et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688PubMed

32.

Gehl J, Boesgaard M, Paaske T et al (1996) Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687PubMedCrossRef

33.

Lluch A, Ojeda B, Colomer R et al (2000) Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. Cancer 89:2169PubMedCrossRef

34.

Rahman Z, Champlin R, Rondon G et al (1997) Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24:S17

35.

Giordano SH, Booser DJ, Murray JL et al (2002) A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8:3360PubMed

36.

Biganzoli L, Cufer T, Bruning P et al (2003) Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial. Cancer 97:40PubMedCrossRef

37.

Shulman LN, Cirrincione C, Berry DA et al. (2010) Four versus 6 cycles of doxorubicin and cyclophosphamide (AC) or paclitaxel (T) as adjuvant therapy for breast cancer in women with 0–3 positive axillary nodes: CALGB 40101—a 2 × 2 factorial phase III trial: first results comparing 4 versus 6 cycles of therapy. In: Program and abstracts of the 33rd annual San Antonio breast cancer symposium, San Antonio, 8–12 December 2010

38.

Fraser J, Steele N, Zaman AA, Yule A (2011) Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer 47(2):215–220PubMedCrossRef

Title: Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis
Authors: Fausto Petrelli
Karen Borgonovo
Mary Cabiddu
Veronica Lonati
Sandro Barni
Publication date: 01-09-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2121-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis

Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study

Mammographic density and breast cancer risk in White and African American Women

Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women’s Health Initiative observational study

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis

Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer